camrelizumab + lenvatinib + oxaliplatin

Camrelizumab + lenvatinib + oxaliplatin is a combination therapy regimen primarily investigated for the treatment of advanced hepatocellular carcinoma (HCC). This regimen integrates three distinct therapeutic modalities: camrelizumab, a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) to enhance anti-tumor immune responses; lenvatinib, an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), and other tyrosine kinases to inhibit angiogenesis and tumor proliferation; and oxaliplatin, a platinum-based cytotoxic agent that induces DNA cross-linking and apoptosis. The combination is frequently studied in the context of hepatic arterial infusion chemotherapy (HAIC), where oxaliplatin is administered directly into the hepatic artery to maximize local drug concentration in the liver. Research led by institutions such as The Affiliated Hospital of Yanbian University aims to evaluate whether this triple-combination approach provides superior efficacy compared to standard-of-care monotherapies or dual combinations in patients with unresectable or advanced HCC.

Other names

camrelizumab plus lenvatinib plus oxaliplatincamrelizumab combined with lenvatinib and oxaliplatin-based HAIC